A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder

NCT00714688 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

279

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit/ Hyperactivity Disorder

Interventions

DRUG: prolonged release (PR) OROS methylphenidate 54 mg
DRUG: prolonged release (PR) OROS methylphenidate 72 mg
DRUG: Placebo

Sponsor

Janssen-Cilag International NV